Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA),is set to announce its Q114 earnings results on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $11.12 million for the quarter. Investors interested in listening to the company’s conference call can do so using this link. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), shares after opening at $7.45 moved to $7.73 on last trade day and at the end of the day closed at $7.63. Company price to sales ratio in past twelve months was calculated as 31.26 and price to cash ratio as 6.01. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), showed a positive weekly performance of 9.00%.
Gilead Sciences, Inc. (NASDAQ:GILD), beat analysts’ expectations yet again. The company’s financial release indicates that the breakthrough Hepatitis C drug, Sovaldi, is the primary cause of the recent boost in the top and bottom lines of the company. The drug received FDA approval in the last month of FY2013 and immediately brought in $139.4 million in revenue. Gilead Sciences, Inc. (NASDAQ:GILD), shares advanced 2.73% in last trading session and ended the day on $78.83. Gilead Sciences, Inc. (NASDAQ:GILD), return on equity ratio is recorded as 38.90% and its return on assets is 19.10%. Gilead Sciences, Inc. (NASDAQ:GILD), yearly performance is 44.75%.
Inovio Pharmaceuticals Inc (NYSEMKT:INO), announced that it will host a conference call and live webcast to report its first quarter 2014 financial results on Monday, May 12, 2014, at 8:30 a.m. ET. Management will discuss first quarter earnings and expectations for the current and upcoming quarters. Inovio Pharmaceuticals Inc (NYSEMKT:INO), shares moved down 6.25% in last trading session and was closed at $2.40, while trading in range of $ 2.35 – $2.48. Inovio Pharmaceuticals Inc (NYSEMKT:INO), year to date (YTD) performance is -17.24%.
Recently, Galena Biopharma Inc (NASDAQ:GALE), has reported that it would be releasing the results of the first quarter of 2014 soon. The company would also host a conference call in order to discuss these results, Galena Biopharma reported. Galena Biopharma Inc (NASDAQ:GALE), weekly performance is 10.46%. On last trading day company shares ended up $2.64. Galena Biopharma Inc (NASDAQ:GALE), distance from 50-day simple moving average (SMA50) is -5.36%. Analysts mean target Price for the company is $6.67.
Leave a Reply